Voriconazole (Q35179545)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Voriconazole	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

7 August 2017

1 reference

Europe PubMed Central

Voriconazole. (English)

1 reference

Europe PubMed Central

7 August 2017

author name string

LilyAnn Jeu

1

1 reference

Europe PubMed Central

7 August 2017

Frank J Piacenti

2

1 reference

Europe PubMed Central

7 August 2017

Aleksandr G Lyakhovetskiy

3

1 reference

Europe PubMed Central

7 August 2017

Horatio B Fung

4

1 reference

Europe PubMed Central

7 August 2017

publication date

1 May 2003

1 reference

Europe PubMed Central

7 August 2017

Clinical Therapeutics

1 reference

Europe PubMed Central

7 August 2017

25

1 reference

Europe PubMed Central

7 August 2017

5

1 reference

Europe PubMed Central

7 August 2017

1321-1381

1 reference

Europe PubMed Central

7 August 2017

Candidemia in cancer patients: a prospective, multicenter surveillance study by the Invasive Fungal Infection Group (IFIG) of the European Organization for Research and Treatment of Cancer (EORTC)

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980126-1

7 January 2021

based on heuristic

inferred from DOI database lookup

National epidemiology of mycoses survey (NEMIS): variations in rates of bloodstream infections due to Candida species in seven surgical intensive care units and six neonatal intensive care units

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980126-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Nosocomial bloodstream infections in United States hospitals: a three-year analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980126-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Nosocomial infections in medical intensive care units in the United States. National Nosocomial Infections Surveillance System

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980126-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Nosocomial infections in coronary care units in the United States. National Nosocomial Infections Surveillance System.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980126-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Risk factors for candidal bloodstream infections in surgical intensive care unit patients: the NEMIS prospective multicenter study. The National Epidemiology of Mycosis Survey

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980126-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Emerging and reemerging microbial threats. Nosocomial fungal infections

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980126-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Trends in antifungal susceptibility of Candida spp. isolated from pediatric and adult patients with bloodstream infections: SENTRY Antimicrobial Surveillance Program, 1997 to 2000.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980126-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Secular trend of hospital-acquired candidemia among intensive care unit patients in the United States during 1989-1999.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980126-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Aspergillus: rising frequency of clinical isolation and continued susceptibility to antifungal agents, 1994-1999.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980126-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Current and future approaches to antifungal therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980126-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Caspofungin: an echinocandin antifungal agent

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980126-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Investigational antifungal agents.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980126-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Use of voriconazole in treatment of Scedosporium apiospermum infection: case report

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980126-1

7 January 2021

based on heuristic

inferred from DOI database lookup

A new triazole, voriconazole (UK-109,496), blocks sterol biosynthesis in Candida albicans and Candida krusei

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980126-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Genome-wide expression patterns in Saccharomyces cerevisiae: comparison of drug treatments and genetic alterations affecting biosynthesis of ergosterol

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980126-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Voriconazole against fluconazole-susceptible and resistant candida isolates: in-vitro efficacy compared with that of itraconazole and ketoconazole.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980126-1

7 January 2021

based on heuristic

inferred from DOI database lookup

In vitro activities of voriconazole (UK-109,496) and four other antifungal agents against 394 clinical isolates of Candida spp

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980126-1

7 January 2021

based on heuristic

inferred from DOI database lookup

In vitro studies of two triazole antifungal agents (voriconazole [UK-109,496] and fluconazole) against Candida species

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980126-1

7 January 2021

based on heuristic

inferred from DOI database lookup

In vitro activities of ravuconazole and voriconazole compared with those of four approved systemic antifungal agents against 6,970 clinical isolates of Candida spp.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980126-1

7 January 2021

based on heuristic

inferred from DOI database lookup

In-vitro activity of voriconazole (UK-109,496), LY303366 and other antifungal agents against oral Candida spp. isolates from HIV-infected patients

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980126-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Germinated and nongerminated conidial suspensions for testing of susceptibilities of Aspergillus spp. to amphotericin B, itraconazole, posaconazole, ravuconazole, and voriconazole

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980126-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparison of the in-vitro activity of voriconazole (UK-109,496), itraconazole and amphotericin B against clinical isolates of Aspergillus fumigatus

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980126-1

7 January 2021

based on heuristic

inferred from DOI database lookup

In vitro antifungal susceptibilities of Trichosporon species.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980126-1

7 January 2021

based on heuristic

inferred from DOI database lookup

In vitro activities of investigational triazoles against Fusarium species: effects of inoculum size and incubation time on broth microdilution susceptibility test results

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980126-1

7 January 2021

based on heuristic

inferred from DOI database lookup

In Vitro Activity of a New Oral Triazole, BMS-207147 (ER-30346).

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980126-1

7 January 2021

based on heuristic

inferred from DOI database lookup

In-vitro antifungal susceptibility of clinical and environmental Fusarium spp. strains

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980126-1

7 January 2021

based on heuristic

inferred from DOI database lookup

In vitro fungicidal activities of voriconazole, itraconazole, and amphotericin B against opportunistic moniliaceous and dematiaceous fungi

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980126-1

7 January 2021

based on heuristic

inferred from DOI database lookup

In vitro activities of new and conventional antifungal agents against clinical Scedosporium isolates

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980126-1

7 January 2021

based on heuristic

inferred from DOI database lookup

In vitro activities of four novel triazoles against Scedosporium spp

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980126-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparative in-vitro activity of voriconazole (UK-109,496) and six other antifungal agents against clinical isolates of Scedosporium prolificans and Scedosporium apiospermum.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980126-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparison of in vitro activities of voriconazole and five established antifungal agents against different species of dermatophytes using a broth macrodilution method

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980126-1

7 January 2021

based on heuristic

inferred from DOI database lookup

In vitro activities of 10 antifungal drugs against 508 dermatophyte strains

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980126-1

7 January 2021

based on heuristic

inferred from DOI database lookup

In vitro susceptibilities of Candida and Cryptococcus neoformans isolates from blood cultures of neutropenic patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980126-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Pharmacokinetics and safety of voriconazole following intravenous- to oral-dose escalation regimens

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980126-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Safety and pharmacokinetics of oral voriconazole in patients at risk of fungal infection: a dose escalation study

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980126-1

7 January 2021

based on heuristic

inferred from DOI database lookup

In-vitro activity of voriconazole, itraconazole and amphotericin B against filamentous fungi

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980126-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Evaluation of voriconazole pharmacodynamics using time-kill methodology

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980126-1

7 January 2021

based on heuristic

inferred from DOI database lookup

In vitro activities of terbinafine in combination with fluconazole, itraconazole, voriconazole, and posaconazole against clinical isolates of Candida glabrata with decreased susceptibility to azoles

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980126-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Synergism of voriconazole and terbinafine against Candida albicans isolates from human immunodeficiency virus-infected patients with oropharyngeal candidiasis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980126-1

7 January 2021

based on heuristic

inferred from DOI database lookup

In vitro interaction of caspofungin acetate with voriconazole against clinical isolates of Aspergillus spp.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980126-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Prevalence of molecular mechanisms of resistance to azole antifungal agents in Candida albicans strains displaying high-level fluconazole resistance isolated from human immunodeficiency virus-infected patients

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980126-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Azole cross-resistance to ketoconazole, fluconazole, itraconazole and voriconazole in clinical Candida albicans isolates from HIV-infected children with oropharyngeal candidosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980126-1

7 January 2021

based on heuristic

inferred from DOI database lookup

In vitro and in vivo effects of 14alpha-demethylase (ERG11) depletion in Candida glabrata

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980126-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy of voriconazole against invasive pulmonary aspergillosis in a guinea-pig model

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980126-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy of voriconazole in a guinea pig model of disseminated invasive aspergillosis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980126-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy of caspofungin alone and in combination with voriconazole in a Guinea pig model of invasive aspergillosis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980126-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy of voriconazole in treatment of murine pulmonary blastomycosis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980126-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980126-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980126-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Voriconazole: in the treatment of invasive aspergillosis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980126-1

7 January 2021

based on heuristic

inferred from DOI database lookup

A randomized, double-blind, double-dummy, multicenter trial of voriconazole and fluconazole in the treatment of esophageal candidiasis in immunocompromised patients

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980126-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980126-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Successful treatment of cerebral aspergillosis with a novel triazole (voriconazole) in a patient with acute leukaemia.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980126-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical activity of the new triazole drug voriconazole (UK 109, 496) against disseminated hepatosplenic aspergillosis in a patient with relapsed leukemia.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980126-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Voriconazole in the management of invasive aspergillosis in two patients with acute myeloid leukemia undergoing stem cell transplantation.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980126-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Successful treatment with voriconazole of invasive aspergillosis in chronic granulomatous disease

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980126-1

7 January 2021

based on heuristic

inferred from DOI database lookup

An unusual case of pulmonary invasive aspergillosis and aspergilloma cured with voriconazole in a patient with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980126-1

7 January 2021

based on heuristic

inferred from DOI database lookup

A multidrug, including voriconazole, resistant oral Candida infection in an AIDS patient effectively treated with echinocandin

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980126-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Successful treatment of Candida glabrata myocarditis with voriconazole

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980126-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Successful outcome of Scedosporium apiospermum disseminated infection treated with voriconazole in a patient receiving corticosteroid therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980126-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Pseudallescheria boydii brain abscess successfully treated with voriconazole and surgical drainage: case report and literature review of central nervous system pseudallescheriasis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980126-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Meningitis caused by Pseudallescheria boydii treated with voriconazole

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980126-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Voriconazole treatment of disseminated paecilomyces infection in a patient with acquired immunodeficiency syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980126-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Cutaneous infection caused by Paecilomyces lilacinus in a renal transplant patient: treatment with voriconazole

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980126-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Successful treatment of Paecilomyces lilacinus endophthalmitis with voriconazole

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980126-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Successful treatment of ocular invasive mould infection (fusariosis) with the new antifungal agent voriconazole

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980126-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Sputum isolation of Wangiella dermatitidis in patients with cystic fibrosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980126-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Disseminated fungal infection following falciparum malaria.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980126-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Voriconazole in the treatment of aspergillosis, scedosporiosis and other invasive fungal infections in children

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980126-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Muco-cutaneous retinoid-effects and facial erythema related to the novel triazole antifungal agent voriconazole.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980126-1

7 January 2021

based on heuristic

inferred from DOI database lookup

The safety of voriconazole

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980126-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of voriconazole on the pharmacokinetics of cyclosporine in renal transplant patients

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980126-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Voriconazole inhibition of the metabolism of tacrolimus in a liver transplant recipient and in human liver microsomes

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980126-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Practice guidelines for diseases caused by Aspergillus. Infectious Diseases Society of America

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980126-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0149-2918(03)80126-1

1 reference

Europe PubMed Central

7 August 2017

1 reference

Europe PubMed Central

7 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q35179545&oldid=1633914854"